Safety of Esophageal Variceal Ligation in Patients on Antiplatelet Therapy

Bleeding Risk Considerations

Esophageal variceal ligation (EVL) is an effective procedure for treating esophageal varices, but it inherently creates shallow ulcers at the ligation sites that may bleed, with post-EVL ulcers occurring in approximately 14% of cases 1, 2
The American Association for the Study of Liver Diseases recommends that EVL be performed with caution in patients on antiplatelet therapy, due to the increased risk of bleeding 1, 2

Proton pump inhibitors (PPIs) should be administered after EVL to reduce the size of post-EVL ulcers and potentially decrease the risk of post-EVL ulcer bleeding, with pantoprazole (40 mg IV after EVL followed by 40 mg oral daily for 9 days) significantly reducing the size of post-EVL ulcers compared to placebo 1, 2
The American College of Gastroenterology recommends the use of PPI therapy before and after EVL to reduce ulcer size and potential bleeding risk in patients on antiplatelet therapy 1, 2

EVL sessions are typically repeated at 7-14 day intervals until variceal obliteration, which usually requires 2-4 sessions, with the most common complications being transient dysphagia and chest discomfort 1
Severe complications such as ulcer bleeding at the ligation site are more likely with EVL than with non-selective beta-blockers, according to the American Association for the Study of Liver Diseases 2

The American Heart Association recommends assessing the indication and urgency of the EVL procedure in patients on antiplatelet therapy, and considering whether it can be delayed until antiplatelet therapy is completed 2, 3
For urgent EVL, the procedure should proceed with additional precautions, including the use of PPI therapy before and after the procedure to reduce ulcer size and potential bleeding risk 1, 3
Close monitoring post-procedure with readiness to manage potential bleeding complications is essential, according to the American College of Cardiology 3

For primary prophylaxis of variceal bleeding, non-selective beta-blockers (propranolol or nadolol) or carvedilol may be considered as alternatives to EVL in patients at high bleeding risk due to antiplatelet therapy, according to the American Association for the Study of Liver Diseases 2, 4